bluebird bio Stock News

March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys

bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.

Bluebird Bio is short on capital and has major new expenses to cover. Meanwhile, its pipeline of drug candidates is looking very weak.

Bluebird Bio's most recently approved gene editing therapy looks highly promising. Novavax has generated decent revenue from its coronavirus vaccine.

Bluebird Bio has accomplished something few gene-editing specialists have matched. However, the biotech could struggle to keep its operations running for a long time.

A top bank cut its price target on the shares by 25%, but it still feels they could more than double in price. Bluebird's fortunes have been mixed, to say the least, and it remains quite a risky inves

bluebird bio (BLUE) revenues miss the Zacks Consensus Estimate in the fourth quarter. The company progresses with the launch of its three approved gene therapies.

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss fourth quarter and 2023 annual results and business updates on Marc

bluebird (BLUE) obtains a $175 million five-year, term loan facility from Hercules that stretches its cash runaway by two years. The company's shares rise on the news.

The commercial-stage biotech has secured a nine-figure loan facility. This potentially gives it access to as much as $175 million in debt funding.

Bluebird Bio has three gene-editing products on the market. However, it will face issues delivering these therapies to patients.

An analyst made a very deep price-target cut on the shares. He reduced his level by 56%.

It isn't often that you can find the right story at the right time to give you a good chance of multiplying your wealth; these so-called multi-bagger stocks get their name because their price sees a p

Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT from CRISPR Therapeutics AG NASDAQ: CRS